Allen Seylani: A Small RNA With a Big Grip on Cholesterol and Heart Disease
Allen Seylani, Scientific Reviewer at Oxford University Press, Resident Physician at Cleveland Clinic, shared a post on LinkedIn about a recent article by Xiuchun Li et al. published in Nature Communications:
“A Small RNA With a Big Grip on Cholesterol and Heart Disease
Huge credit to Changcheng Zhou professor of medicine and biomedical sciences at University of California, Riverside University of California, Riverside Internal Medicine department and his team.
Using an advanced sequencing approach that reveals RNA species we have been missing, the authors identify a liver enriched tRNA derived small RNA called tsRNA Glu CTC as the most abundant small RNA in the liver.
This molecule is cholesterol responsive, moves into the nucleus, binds SREBP2, and amplifies transcription of the very pathway that governs cholesterol synthesis. When tsRNA Glu CTC is increased, mice develop hypercholesterolemia, hepatic steatosis, fibrosis, and accelerated atherosclerosis.
When it is silenced with antisense therapy, LDL levels fall, liver fat improves, and atherosclerotic plaque burden shrinks. Even more striking, the naturally modified version of this RNA is far more potent than synthetic RNA, highlighting how RNA chemistry itself shapes disease biology.
This is not just a new pathway. It is a new layer of regulation that sits above the classic statin and PCSK9 paradigm and directly tunes SREBP2 activity. It reframes noncoding RNA as an active transcriptional regulator in cardiometabolic disease and opens the door to RNA targeted therapies that act upstream of cholesterol synthesis itself.
For anyone interested in cardiology, metabolism, RNA biology, or therapeutic innovation, this is worth a close read. It is a reminder that some of the most powerful regulators in biology are the ones we could not see until now.
This discovery opens the door for places like Cleveland Clinic, a leader in cardiovascular medicine, to lead the field in translating tsRNA based biomarkers and antisense therapies into precision tools that target cholesterol biology at its transcriptional core rather than its downstream consequences.”
Title: A cholesterol-responsive hepatic tRNA-derived small RNA regulates cholesterol homeostasis and atherosclerosis development
Authors: Xiuchun Li, Rebecca Hernandez, Xudong Zhang, Sijie Tang, Xiaohong Yuan, Jing Wu, Kathy Pham, Hukam C. Rawal, Erica C. Heinrich, Shenglong Zhang, Qi Chen, Tong Zhou, Changcheng Zhou
Read the Full Article on Nature Communications
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Mar 20, 2026, 17:47Julie Rayes: Commenting on a Seminal NEJM Study Solving the Mystery of VITT
-
Mar 20, 2026, 17:45William Tembo: Advancing Stroke Care by Validating Acute Ischemic Treatment
-
Mar 20, 2026, 17:37Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
-
Mar 20, 2026, 17:35Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
-
Mar 20, 2026, 17:17Angelo Cascio Rizzo: CTA-Based Plaque RADS Improves Risk Stratification in ESUS
-
Mar 20, 2026, 17:09Clinical Practice Guidelines for Platelet Transfusion in Non-Surgical and Non-Traumatic Settings – CEBaP
-
Mar 20, 2026, 17:07The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
-
Mar 20, 2026, 17:05Pierre Fontana: Launching the European Interuniversity Certificate in Clinical Haemostasis
-
Mar 20, 2026, 16:49Wolfgang Miesbach: A Pivotal Step Forward for Patients with von Willebrand Disease Across All Subtypes